Agenus | AGEN - Interest Expense On Debt


Agenus reported $16.02M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Agenus USD 16.02M 2.85M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 582K 10K Dec/2025
Intrexon USD 2K 5K Jun/2024
J&J USD 18M 290M Sep/2025
Jiangsu Hengrui CNY 254.59M 253.85M Sep/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck EUR 121M 5M Dec/2025
Merck USD 412M 85M Dec/2025
Northwest Biotherapeutics USD 1.52M 276K Mar/2024
Novartis USD 304M 23M Dec/2025
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023